Bibliobiftek - Re: Aravive - Platinum Resistant Ovarian Cancer
"The actual results of therapies using IMGN technology have been as good if not better so far than those using SGEN technology."
Your statement reveals that the true problem has been poor management decisions over the years, not the technology. That is the frustration in owning this stock.
I was hoping that Mark Enyedy would have changed all of this but so far not the case.
They better get it "right" soon.
With that said, it is still a great stock to buy low and sell higher to make profit if you are not concern about hitting the jackpot.